An ARC, or Antibody-Radionuclide-Conjugate, comprises three components:
- a targeting molecule, such as a monoclonal antibody, that seeks out and binds to specific molecules on the surface of tumour cells,
- a radionuclide payload that kills the tumour cells, and
- a chemical linker that entraps the radionuclide and binds it to the targeting molecule
Nordic Nanovector’s vision is to become a leading provider of ARC clinical solutions, addressing major unmet medical needs and advancing cancer care through its innovative therapy programmes and patented technologies.